isoproterenol has been researched along with spironolactone in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (18.18) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 12 (54.55) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brockmöller, J; Dücker, C; Gebauer, L; Jensen, O | 1 |
| Wexler, BC | 1 |
| Eandi, M; Miocchi, D; Ricci Gamalero, S | 1 |
| Ramdohr, B | 1 |
| Moudgil, LR | 1 |
| Christ, M; Falkenstein, E; Günther, A; Heck, M; Schmidt, BM; Wehling, M | 1 |
| Casis, O; Echevarria, E; Espiña, L; Gallego, M; Iriarte, MM; Vegas, L | 1 |
| Christ, M; Kirsch, E; Lombès, M; Viengchareun, S; Wehling, M; Zennaro, MC | 1 |
| Deftereos, DA; Gray, D; Norton, GR; Osadchii, O; Veliotes, DG; Woodiwiss, AJ | 1 |
| Badenhorst, D; Brooksbank, R; Correia, RJ; Norton, GR; Strijdom, H; Veliotes, DG; Woodiwiss, AJ | 1 |
| Higuchi, S; Hori, Y; Hoshi, F; Itoh, N; Kanai, K; Yoshioka, K | 1 |
| Canan, BD; Chimanji, NS; Delfín, DA; Ganguly, R; Janssen, PM; Martin, CD; Mays, TA; Murray, JD; Rafael-Fortney, JA; Raman, SV; Schill, KE; Stangland, JE; Tran, T; Xu, Y | 1 |
| Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D | 1 |
| Goyal, BR; Mehta, AA | 1 |
| Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM | 1 |
| Alonso, MJ; Clerici, SP; Davel, AP; Jaffe, IZ; Palacios, R; Rossoni, LV; Vassallo, DV; Victorio, JA | 1 |
| Cai, J; Chen, L; Chen, X; Zheng, G; Zhou, H; Zhou, X | 1 |
| Hori, Y; Hoshi, F; Itoh, N; Kanai, K; Saitoh, R; Touei, D; Yamagishi, M | 1 |
1 review(s) available for isoproterenol and spironolactone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
21 other study(ies) available for isoproterenol and spironolactone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
Topics: Biological Transport; Cations; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2 | 2022 |
Opposing effects of deoxycorticosterone and spironolactone on isoprenaline-induced myocardial infarction.
Topics: Animals; Body Weight; Corticosterone; Desoxycorticosterone; Isoproterenol; Lipids; Male; Myocardial Infarction; Organ Size; Rats; Spironolactone; Water-Electrolyte Balance | 1979 |
Response to nor-epinephrine, isoprenaline and spironolactone derivatives in normal and hypertensive rats.
Topics: Animals; Blood Pressure; Canrenoic Acid; Heart Rate; Hypertension, Renal; Isoproterenol; Norepinephrine; Rats; Spironolactone; Time Factors | 1979 |
Drug therapy in cardiogenic shock.
Topics: Cardiac Output; Digitalis Glycosides; Dopamine; Glucagon; Hemodynamics; Humans; Isoproterenol; Metaproterenol; Myocardial Infarction; Norepinephrine; Phentolamine; Plasma Substitutes; Shock, Cardiogenic; Spironolactone | 1973 |
Possible protective action of antialdosterone compounds in myocardial necrosis in rats.
Topics: Animals; Cardiomyopathies; Isoproterenol; Mineralocorticoid Receptor Antagonists; Necrosis; Rats; Spironolactone | 1969 |
Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells.
Topics: 1-Methyl-3-isobutylxanthine; Adenylyl Cyclases; Aldosterone; Animals; Calcium Signaling; Coronary Vessels; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cycloheximide; Estradiol; Gene Expression Regulation; Hydrocortisone; Isoproterenol; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Phosphorylation; Protein Processing, Post-Translational; Protein Synthesis Inhibitors; Spironolactone; Swine; Sympathomimetics; Transcription, Genetic | 1999 |
Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomegaly; Collagen; Dose-Response Relationship, Drug; Endomyocardial Fibrosis; Heart Ventricles; Isoproterenol; Myocardium; Organ Size; Rats; Rats, Sprague-Dawley; Spironolactone; Ventricular Remodeling | 2001 |
Enhancement of beta-adrenergic cAMP-signaling by the mineralocorticoid receptor.
Topics: Adrenergic beta-Agonists; Aldosterone; Animals; Cell Line; Cyclic AMP; G-Protein-Coupled Receptor Kinase 3; Gene Expression Regulation; GTP-Binding Protein alpha Subunits; Humans; Isoproterenol; Kidney; Peptide Fragments; Protein Serine-Threonine Kinases; Rabbits; Receptor Cross-Talk; Receptors, Adrenergic, beta-2; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Transfection | 2005 |
Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation.
Topics: Adrenergic beta-Agonists; Animals; Collagen; Echocardiography; Heart; Hypertension; Hypertrophy, Left Ventricular; Isoproterenol; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Norepinephrine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Mineralocorticoid; Spironolactone; Systole; Ventricular Dysfunction, Left; Ventricular Remodeling | 2005 |
Impact of aldosterone receptor blockade on the deleterious cardiac effects of adrenergic activation in hypertensive rats.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Blood Pressure; Cardiomyopathy, Dilated; Hypertension; Hypertrophy, Left Ventricular; Isoproterenol; Matrix Metalloproteinase 2; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Mineralocorticoid; Renin-Angiotensin System; Spironolactone | 2010 |
Spironolactone decreases isoproterenol-induced ventricular fibrosis and matrix metalloproteinase-2 in rats.
Topics: Animals; Fibrosis; Gene Expression Regulation, Enzymologic; Heart Diseases; Isoproterenol; Male; Matrix Metalloproteinase 2; Myocardium; Rats; Rats, Inbred WKY; Spironolactone | 2011 |
Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.
Topics: Animals; Cardiac Imaging Techniques; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; Diuretics; Isoproterenol; Lisinopril; Magnetic Resonance Imaging; Mice; Mice, Inbred mdx; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Myocardium; Spironolactone | 2011 |
Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Fibrosis; Heart; Immediate-Early Proteins; Inflammation; Isoproterenol; Male; Mineralocorticoid Receptor Antagonists; Oxidation-Reduction; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone | 2012 |
Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Algorithms; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; C-Reactive Protein; Cardiomegaly; Creatine Kinase, MB Form; Disease Models, Animal; Diuretics; Drug Therapy, Combination; Dyslipidemias; Hemodynamics; Injections, Intraperitoneal; Isoproterenol; Rats; Rats, Wistar; Spironolactone; Telmisartan; Treatment Outcome | 2012 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, Animal; Down-Regulation; Heart Failure; Isoproterenol; Male; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Valine; Valsartan | 2013 |
Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue.
Topics: Adipose Tissue; Analysis of Variance; Animals; Cardiomegaly; Disease Models, Animal; Isoproterenol; Losartan; Male; Nitric Oxide Synthase Type III; Random Allocation; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Renin-Angiotensin System; Role; Spironolactone; Vasoconstriction | 2016 |
Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial-Mesenchymal Transition.
Topics: Actins; Animals; Antigens, CD; Cadherins; Cardiotonic Agents; Collagen Type I; Collagen Type III; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Endomyocardial Fibrosis; Epithelial-Mesenchymal Transition; Human Umbilical Vein Endothelial Cells; Humans; Isoproterenol; Male; Myocardium; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Sprague-Dawley; Relaxin; Spironolactone; Transforming Growth Factor beta; Vimentin | 2017 |
The Aldosterone Receptor Antagonist Eplerenone Inhibits Isoproterenol-Induced Collagen-I and 11β-HSD1 Expression in Rat Cardiac Fibroblasts and the Left Ventricle.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenergic beta-Agonists; Animals; Cells, Cultured; Collagen Type I; Eplerenone; Fibroblasts; Fibrosis; Heart Ventricles; Isoproterenol; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Inbred WKY; Spironolactone | 2017 |